Anti-VEGF medications such as bevacizumab, ranibizumab, aflibercept, and, most recently, brolucizumab, can be delivered into the intravitreal space and reduce the extent of exudative AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.